Many factors increase the complexity of the biologics landscape and the adoption of biosimilars in the U.S. To identify actions that can support the further development and use of biosimilars in the U.S. health care system, and to provide consistent and accurate messages about the value of biosimilars, AMCP held a multidisciplinary stakeholder virtual forum from December 15–16, 2020. Forum participants represented diverse sectors of the healthcare industry, including integrated delivery systems, health plans, pharmacy benefit managers (PBMs), employer groups, biopharmaceutical companies, patient advocacy organizations, health policy researchers, and consulting firms; they considered the strength of different messages and identified gaps in messaging as well as real-world evidence needs. This discussion led to recommendations for language alignment, education, and other ways to improve biosimilar adoption.


  • Sonia Oskouei, PharmD, BCMAS, DPLA
  • Vice President, Biosimilars
  • Cardinal Health
  • Carly Rodriguez, PharmD, FAMCP
  • Pharmacy Director, Clinical Innovation
  • Moda Health

** IMPORTANT: AMCP webinars are limited to the first 1000 that join the webinar. AMCP will provide a link to the recording and slides to all registrants within one week from the webinar date.

Click here for additional information and registration details.


Related Content

Evidence Matters 2022

Evidence Matters 2022

Evidence Matters is a virtual one-day summit that brings the literature review community together from different industries to learn, engage, and solve ever-pressing evidence-based research challenges.